Drug updated on 12/11/2024
| Dosage Form | Injection (intravenous; 148 MBq/mL to 3,700 MBq/mL [4 mCi/mL to 100 mCi/mL]) |
| Drug Class | Radioactive diagnostic agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.
Latest News
Summary
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- The pooled sensitivity and specificity of F-18 fluoroestradiol (F-18 FES) positron emission tomography (PET)/computed tomography (CT) for assessing estrogen receptor expression in patients with recurrent or metastatic breast cancer were 0.86 and 0.85, respectively, demonstrating high diagnostic accuracy.
- The study focused specifically on patients with recurrent or metastatic breast cancer, with no further subgroup analyses provided.
- No comparative effectiveness data with other drugs were available in the study.
- The primary safety concern reported for F-18 FES PET/CT was injection site pain, which was attributed to mechanical injury from the needle rather than the radioactive material itself.
- No significant adverse effects were reported in the study, and the test was deemed safe overall.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Cerianna (fluoroestradiol F 18) Prescribing Information. | 2024 | GE Healthcare., Wauwatosa, WI |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| 18F-fluoroestradiol positron emission tomography in patients with breast cancer: a systematic review and meta-analysis | 2023 | Revista da Associacao Medica Brasileira |
| Safety and Effectiveness of F-18 Fluoroestradiol Positron Emission Tomography/Computed Tomography: a Systematic Review and Meta-analysis | 2021 | Journal of Korean medical science |